

Nucleotide sequence of the cDNA encoding human tyrosinase-related protein

Tirza Cohen⁺, Rita M. Muller, Yashushi Tomita¹ and Shigeki Shibahara^{2,*}

Friedrich Miescher-Institut, PO Box 2543, CH-4002 Basel, Switzerland and ¹Department of Dermatology and ²Department of Applied Physiology, Tohoku University School of Medicine, Sendai 980, Japan

Submitted March 29, 1990

EMBL accession no. X51420

We have isolated a pigment cell-specific cDNA, pMT4, from B16 mouse melanoma cDNA library by differential hybridization (1) and initially considered that it codes for tyrosinase, an essential enzyme of melanin biosynthesis (1). However, the pMT4 was shown to map to the brown (*b*) locus (2) that determines the type of melanin produced, which is inconsistent with the assumption that tyrosinase is encoded at the *c* locus (3). Subsequently, the protein encoded by pMT4 was shown to possess no tyrosinase activity in transient expression assays (4) and tentatively termed tyrosinase-related protein (TRP) (2), since mouse TRP shares 40% amino acid homology with the sequence of mouse tyrosinase (4). Here we present the nucleotide and deduced amino acid sequence of the cDNA coding for human TRP, a homologue to mouse *b* locus gene product. Two cDNA clones were isolated from a cDNA library of S7 human melanoma cells (5), constructed in the Okayama-Berg vector (6), by using the mouse TRP cDNA, pMT4, as a hybridization probe. The assigned reading frame codes for a polypeptide of 527 amino acids with a molecular weight of 60,000, including a putative signal peptide of 24 amino acids (indicated by negative numbers). Human TRP is shorter than mouse TRP by ten amino acids at the carboxy terminus and the degree of sequence homology is about 93%.

REFERENCES

- Shibahara, S., Tomita, Y., Sakakura, T., Nager, C., Chaudhuri, B. and Muller, R. (1986) *Nucl. Acids Res.* **14**, 2413–2427.
- Jackson, I. J. (1987) *Proc. Natl. Acad. Sci. USA* **85**, 4392–4396.
- Coleman, D. L. (1962) *Arch. Biochem. Biophys.* **69**, 562–568.
- Muller, G., Ruppert, S., Schmid, E. and Schutz, G. (1988) *EMBO J.* **7**, 2723–2730.
- Bruggen, J., Macher, E. and Sorg, C. (1981) *Cancer Immunol. Immunother.* **10**, 121–127.
- Okayama, H. and Berg, P. (1982) *Mol. Cell. Biol.* **2**, 161–170.

```

AATCTAAGAGAAGTTCATCAGAGACATCCTTCAGGATTGTGAGCTGGATTTCTCCTAC 60
GTGCTTCAGTCTCTCTACACAAGAGCTGCAAAACAGGCTTTGTTTTGCACTCTTATT 120
TCAAGCAGAATGAGTGCCTAAACTCCTCTCTCTGGCTGTATCTCTCCCTGGCTA 180
MetSerAlaProLysLeuLeuSerLeuGlyCysLysPhePheProLeuLeu
-20
CTTTTTCAGCAGGCCCGGCTCAATCCCAAGACAGTGGCCACTGTTGAGGCTTTGAGA 240
LeuPheGlnGlnAlaArgAlaGlnPheProArgGlnCysAlaThrValGluAlaLeuArg
-1 1 10
AGTGGTATGTGTTGCCAGACCTGTCCTCTGTGCTGGGCTGGGACAGACCGCTGTGGC 300
SerGlyMetCysCysProAspLeuSerProValSerGlyProGlyThrAspArgCysGly
20 30
TCATCATCAGGGAGGGGCGATGTGAGGCGAGTGCAGACTCCCGGCCCCACAGCCCT 360
SerSerSerGlyArgGlyArgCysGluAlaValThrAlaAspSerArgProHisSerPro
40 50
CAGTATCCCATGATGGCAGAGATGATCGGGAGGCTCGGCCCTTGGCTTCTCAATAGG 420
GlnTyrProHisAspGlyArgAspArgGluValTrpProLeuArgPhePheAsnArg
60 70
ACATGTCACTGCAACGGCAATTTCTCAGGACACAAGTGGGACGTGGCCCTCTGGCTGG 480
ThrCysHisCysAsnGlyAsnPheSerGlyHisAsnCysGlyThrCysArgProGlyTrp
80 90
AGAGGAGCTGCTGTGACCAGAGGGTTCTCATAGTCAGGAGAAATCTTGGACTTAAGT 540
ArgGlyAlaAlaCysAspGlnArgValLeuLeuValArgArgAsnLeuLeuAspLeuSer
100 110
AAAGAAGAAAAGAACCACTTTGCCGGCCCTGGATATGGCAAAGCCCACTCACCCCT 600
LysGluGluLysAsnHisPheValArgAlaLeuAspPheAlaLysArgThrHisPro
120 130
TTATTTGTCATTGCCACGAGGATCAGAGAATACTGGGGCCAGATGGCAACAGCCCA 660
LeuPheValIleAlaThrArgArgSerGluGluIleLeuGlyProAspGlyAsnThrPro
140 150
CAATTTGAGAACATTTCCATTATAACTACTTTGTTGGACACACTATTACTCAGTCAA 720
GlnPheGluAsnIleSerIleTyrAsnTyrPheValTrpThrHisTyrTyrSerValLys
160 170
AAGACTTCTCTGGGTAGGACAGGAAAGCTTTGGTGAAGTGGATTCTCTCATGAGGGA 780
LysThrPheLeuGlyValGlyGlnGluSerPheGlyGluValAspPheSerHisGluGly
180 190
CAGCTTTTCTCACATGGCACAGGTTACCCTCTGCTGCTGGAGAAAGACATCGAGGAA 840
ProAlaPheLeuThrTrpHisArgTyrHisLeuLeuArgLeuGluLysAspMetGlnGlu
200 210
ATGTTGCAAGAGCCTTCTTCTCCCTTCTACTGGAATTTTGGCAAGGGGAAAATGTC 900
MetLeuGlnGluProSerPheSerLeuProTyrTrpAsnPheAlaThrGlyLysAsnVal
220 230
TGTGATATCTGCACGGATGACTTGTATGGGATCCAGAAGCAACTTTGATCCACTTAATA 960
CysAspIleCysThrAspAspLeuMetGlySerArgSerAsnPheAspSerThrLeuIle
240 250
AGCCCAAACCTGTCTTTTCTCAATGGGAGTGGCTGTGACTCTTGGAGATTTATGAT 1020
SerProAsnSerValPheSerGlnTrpArgValValCysAspSerLeuGluAspTyrAsp
260 270
ACCTTGGGAACACTTTGTAACAGCACAGGATGGGCAATTAGGAGAAATCCAGCTGGA 1080
ThrLeuGlyThrLeuCysAsnSerThrGluAspGlyProIleArgArgAsnProAlaGly
280 290
AATGGCCAGACCAATGGTCAACGCTTCTCTGAAACACAGGATGTCGCTCAGTGCTTG 1140
AsnValAlaArgProMetValGlnArgLeuProGluProGlnAspValAlaGlnCysLeu
300 310
GAATCTGGTTTATTGGACACCTCTCTTTTATCCCACTCAACAACAGTTCCGAAAC 1200
GluValGlyLeuPheAspThrProPheTyrSerAsnSerThrAsnSerPheArgAsn
320 330
ACAGTGGAAAGTTACAGTGACCCACGGGAAAGTATGACCTGCTGTTCCGAAGTCTTAC 1260
ThrValGluGlyTyrSerAspProThrGlyLysTyrAspProAlaValArgSerLeuHis
340 350
AATTTGGCTCATCTATTCTGAATGGAACAGGGGCAAAACCCATTGTCTCCAAATGAT 1320
AsnLeuAlaHisLeuPheLeuAsnGlyThrGlyGlyGlnThrHisLeuSerProAsnAsp
360 370
CCTATTTTGTCTCTGCACACTTCCAGATGCACTTTTGTGAAATGGCTGAGGAGA 1380
ProIlePheValLeuLeuHisThrPheThrAspAlaValPheAspGluTrpLeuArgArg
380 390
TACAATGCTGATATATCCACATTTCCATTGGAAAATGCCCTATTGGACATAATAGACAA 1440
TyrAsnAlaAspIleSerThrPheProLeuGluAsnAlaProIleGlyHisAsnArgGln
400 410
TACAACATGGTCCATCTTGGCCCCAGTCACCAACACAGAAATGTTGTTACTGCTCCA 1500
TyrAsnMetValProPheTyrProProValThrAsnThrGluMetPheValThrAlaPro
420 430
GACAACCTGGGATACACTTATGAAATCAATGGCCAAAGTCGGAGTTTGTGTACTCTGAG 1560
AspAsnLeuGlyTyrThrTyrGluIleGlnTrpProSerArgGluPheSerValProGlu
440 450
ATAATTGCCATAGCAGTAGTGGCGCTTTGTTACTGGTGCCTCATTTTGGGACTGCT 1620
IleIleAlaIleAlaValValGlyAlaLeuLeuValAlaLeuIlePheGlyThrAla
460 470
TCTTATCTGATTCTGGCCGACGCACTGATGATGAAGCTAACGACCTCTCACTGAT 1680
SerTyrLeuIleArgAlaArgSerMetAspGluAlaAsnGlnProLeuLeuThrAsp
480 490

```

* To whom correspondence should be addressed

⁺Present address: Department of Human Genetics, Hadassah Hospital, POB 12000, 91120 Jerusalem, Israel

CAGTATCAATGCTATGCTGAAGAAAGAATATGAAAACTCCAGAATCCTAATCAGTCTGT 1740
GlnTyr:GlnCysTyr:AlaGluGluArgIleEnd
500
GGTCTAAACAAATGCCCTACTCTCTTATGCATTAGTATCACAAAACACCTGGTTGAATAT 1800
AATAGATTGAGTTATAACTGTATTTTCTTTCACTTTATTACCTTCCTTCTAATACAAGC 1860
ATATGTTAGCATTAAAGTTCTAGGCATACTTTCAAAGCTGGGAAGACCCCTTCAGAATC 1920
TTTTCAATGGGTTTTAATTTTCAGTCTATTTAAAATGGTGAATGACACTAACTCCATG 1980
ATATTTAAGGATAGTGTGAAGATCTTTGGCATGATTTAAAGTTGAGTATGTGAAGATAT 2040
AAGTGAACACCATGCTTTGTTTACGTGTAAGGAAAATAATGTTGATAGTAAATGTCC 2100
ACTTAAATACATGAATGGGCATTTCTAAAATGTAAAACATAAACACATTTCCATTCTAT 2160
GGATATTTGTCAACAGATTTAAAGAAAACACAGTTATTAATTAAGAAAAATTAATTATG 2220
TGATGTTATAAACCAATGAAATTTGATTAACCTTTTCAAATTAATGTTCCAGTTTGAAG 2280
ACCAATCAAATATATTTAGTCAACATATACTATTTAGTCTCAGGTTCAAGGTACAA 2340
CAAAAATCACCATCTTTGTCAAACCTTTGGAGAGGAAAATCTTCACCTTCTTAAGCAACA 2400
ATGGATATTGCCTGTGTTTGCACCTGTGTTTCCTGCCTCTCAATTCGCTGAAAAAGGAA 2460
CTACCTATCCTTACATTTACCTACTAATGTCTCTTCTAACATCTTAGAGGTCATGGAG 2520
AAGGCATATGGAGAACATGTTTTATACTGCTCTATAAATAGTATTCCAATCACTGTGCTT 2580
AATTTAAATAGCATTATCTTATCATTATCAGCCTTTTATGATTTTCCAAGTAAAAATAT 2640
TAACATATTTTTCATTTGCTCTCTTTTTATCTGGTCTATATGAATGCTATTTTTTCC 2700
CTTCTCTTCTAACATGAAATATATTTTCTCTTTTTGATCTTGTGCTATGAAACAACTTA 2760
CCAAAGAACTGTATAAGGTGGTCATAAGTGAATTTTTAATTAATAATGGTAAAAATAAA 2820
AAAAAAAAATAAAAAAT 2837